FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Miller-Rich Nancy					2. Issuer Name and Ticker or Trading Symbol Aldeyra Therapeutics, Inc. [ ALDX ]								(Ch	Relationship ( eck all applic X Directo	or		on(s) to Issuer 10% Owner	
(Last) (First) (Middle) C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 06/08/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)								6.1	Officer (give title Other (specify below)  6. Individual or Joint/Group Filing (Check Applicable				
(Street) LEXINGTON MA 02421  (City) (State) (Zip)				4. II Americanent, Date of Original Flied (Montuin Day) feat)							Lin	X Form filed by One Reporting Person Form filed by More than One Reporting Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transar Date (Month/Date			Execution Date,			3. 4. Securities Acquired (A) Transaction Code (Instr. 5) Todo (Instr. 3, 4)				Beneficia Owned F	es For ally (D) Following (I) (		Direct of Endirect Etr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code V	Amo	unt	(A) or (D)	Price		nsaction(s) htr. 3 and 4)		(1	(Instr. 4)	
		-							uired, Dis s, options,					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, Tr	ansaction ode (Instr.				6. Date Exerc Expiration Day (Month/Day/)	ate	nd	7. Title and of Securiti Underlying Derivative (Instr. 3 an	es Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				C	ode	v	(A)	(D)	Date Exercisable	Expirati Date	ion	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$12.97	06/08/2021			A		13,534		(1)	06/07/20	031	Common Stock	13,534	\$0.00	13,534	•	D	
Stock Option (Right to Buy)	\$12.97	06/08/2021			A		583		(2)	06/07/20	031	Common Stock	583	\$0.00	583		D	

## **Explanation of Responses:**

- 1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
- 2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.

## Remarks:

/s/ Nancy Miller-Rich

\*\* Signature of Reporting Person

06/10/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.